Recombinant Leptin Therapy for Nonalcoholic Steatohepatitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective therapies for nonalcoholic steatohepatitis (NASH), a progressive metabolic liver disease characterized by fatty liver infiltration, insulin resistance, and inflammation, with no standard management options available, and current treatments for obesity-related conditions do not adequately address liver histopathology or metabolic improvements.
Innovation Solution
Administering recombinant leptin to non-lipodystrophic subjects with relative leptin deficiency to increase mean serum leptin concentration, thereby reducing hepatic lipid content, improving insulin sensitivity, and modulating gene expression associated with lipogenesis and lipid oxidation, which helps in treating NASH and other fatty liver conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current treatments for obesity-related conditions are used, then weight management may be improved, but liver histopathology and metabolic improvements are not adequately addressed
Solution Approach 1:
The patent identifies relative leptin deficiency as a key parameter in NASH pathogenesis and uses recombinant leptin therapy to change the leptin concentration parameter in serum, thereby directly addressing liver fat content and metabolic abnormalities that conventional obesity treatments fail to correct
Solution Approach 2:
Recombinant leptin acts as an intermediary substance that mediates between adipose tissue signaling and hepatic lipid metabolism, providing the specific metabolic signaling that is deficient in NASH patients and is not adequately provided by conventional obesity treatments
2Manufacturing precision
If standard management options are used for NASH, then general obesity management may be maintained, but specific liver histopathology improvement is not achieved
Solution Approach 1:
The patent applies leptin therapy specifically to address liver histopathology quality in NASH patients with relative leptin deficiency, providing localized metabolic correction for hepatic tissue while distinguishing this specific application from general obesity management
Solution Approach 2:
The patent segments the NASH treatment approach by identifying a specific subgroup of patients with relative leptin deficiency who would benefit from recombinant leptin therapy, separating this targeted indication from conventional obesity management for the broader population
3Quantity of substance
If leptin therapy is administered to increase serum leptin concentration, then hepatic lipid content decreases and insulin sensitivity improves, but the treatment is specifically for non-lipodystrophic subjects with relative leptin deficiency
Solution Approach 1:
The patent uses parameter change by measuring serum leptin concentration and identifying patients with relative leptin deficiency (lower than expected levels for their adiposity), then administering recombinant leptin to change the leptin parameter to therapeutic levels, achieving hepatic lipid reduction and insulin sensitivity improvement in this specifically defined patient population
Data Source
AI summary
The invention generally relates to the use of leptin in the treatment of a leptin-responsive disease or condition in a non-lipodystrophic subject. More particularly, the invention is directed to the use of leptin in the treatment of a fatty liver disease in a non-lipodystrophic subject with a relative leptin deficiency. The invention includes methods for the treatment of nonalcoholic steatohepatitis (NASH), alcoholic fatty liver disease (AFLD), and nonalcoholic fatty liver disease (NAFLD) in a non-lipodystrophic subject. The invention includes the treatment of conditions ranging from ectopic lipid accumulation (steatosis) to cirrhosis.